Skip to main content

Table 4 Top 10 adverse effects (grade 3–5) associated with gefitinib versus erlotinib

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Grade 3–5 Adverse effects

Gefitinib group (event/total)

Erlotinib group (event/total)

RR (95% CI)

P value

Heterogeneity

I2 (%)

P value

Skin rash

72/999

163/745

0.22 (0.12–0.41)

< 0.00001

73

0.0006

Diarrhea

31/892

38/710

0.46 (0.29–0.74)

0.001

0

0.46

Nausea/Vomiting

8/639

27/531

0.23 (0.11–0.49)

0.0001

20

0.29

Fatigue

18/639

40/531

0.28 (0.09–0.87)

0.03

74

0.02

Anorexia

3/403

4/310

0.25 (0.06–1.04)

0.06

NA

NA

Interstitial lung disease

7/619

3/514

1.05 (0.27–4.06)

0.95

17

0.3

Stomatitis

3/260

8/169

0.28 (0.08–0.99)

0.05

24

0.27

Elevated liver enzymes

80/652

23/400

1.50 (0.97–2.31)

0.07

0

0.64

Infection

9/454

7/380

1.12 (0.46–2.69)

0.8

20

0.28

Neutropenia

2/399

3/379

0.67 (0.11–3.97)

0.66

NA

NA